MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)

P. Kaňovský, D. Gaebler-Spira, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, F. Heinen (Olomouc, Czech Republic)

Meeting: MDS Virtual Congress 2021

Abstract Number: 76

Keywords: Botulinum toxin: Clinical applications: spasticity, Cerebral palsy, Xeomin

Category: Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Objective: To assess the efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy (CP) and Gross Motor Function Classification System (GMFCS) levels IV–V using pooled data from the first injection cycle in two randomized Phase 3 studies, TIM (NCT01893411) and XARA (NCT02002884).

Background: Patients with CP have a wide range of motor impairments with a substantial proportion showing severe impairment (GMFCS level IV or V).

Method: Non-ambulant patients with GMFCS levels IV–V were analyzed (2–17 years of age with uni-/bilateral CP and Ashworth Scale [AS] score ≥2 in clinical patterns for treatment). Patients were randomized to three incobotulinumtoxinA dose groups: 8, 6, 2 U/kg body weight, maximum 200, 150, 50 U, per LL clinical pattern in TIM, and per UL in XARA. Additional multipattern treatment was allowed in both studies with total body doses up to 16 U/kg (≤400 U). Changes from baseline in AS and Global Impression of Change Scale (GICS) scores at Week 4 were assessed in those who had LL treatment (TIM and XARA) and those who had UL treatment (XARA). The incidence of adverse events (AEs) was also assessed.

Results: Of patients with GMFCS levels IV–V, 164 received LL treatment and 108 received UL treatment. Statistically significant improvements in AS score for the pes equinus and flexed elbow/wrist and investigator’s GICS for both the LL and UL were seen with all incobotulinumtoxinA doses at Week 4 in patients with GMFCS levels IV–V and I–III (p<0.0001 vs baseline [table1]). In patients with GMFCS levels IV–V, AS and GICS improvements were numerically greatest in the high-dose group. The frequency of AEs was generally <30.0% across dose groups and GMFCS levels I–V. Fewer patients with GMFCS levels IV–V (21.4%) vs I–III (25.7%) experienced AEs. Few AEs of special interest (IV–V: 1.1%; I–III: 1.3%), treatment-related AEs (IV–V: 0.5%; I–III: 2.5%), or serious AEs (IV–V: 1.6%; I–III: 1.9%) occurred.

Conclusion: IncobotulinumtoxinA was effective, safe, and well-tolerated for multipattern treatment of LL and UL spasticity in children with severe CP (GMFCS levels IV–V).
Presented at TOXINS 2021 (Jan 16–17).

MDS 2021 CP severe patients TABLE

To cite this abstract in AMA style:

P. Kaňovský, D. Gaebler-Spira, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, F. Heinen. Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V) [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/pooled-efficacy-and-safety-analysis-of-incobotulinumtoxina-for-upper-and-lower-limb-spasticity-in-children-with-severe-cerebral-palsy-gmfcs-levels-iv-v/. Accessed May 19, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/pooled-efficacy-and-safety-analysis-of-incobotulinumtoxina-for-upper-and-lower-limb-spasticity-in-children-with-severe-cerebral-palsy-gmfcs-levels-iv-v/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley